In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study
GSK678361 from the very rst day of disease joints with severe changes was 8% for (Fig. 5d). The percentage of animals treated from day 1 of arthritis, compared with 13% for animals treated from day 14. In contrast, untreated or vehicle-treated mice showed 75% and 67% data are illustrated in Fig. 5f.
severely affected joints. These Differential effects of GW856553X on HUVEC responses
To action of GW856553X study the potential mechanism of termined the effect of this inhibitor in a in vivo, we de-panel of assays. In order to determine the effects in vitro endothelial cell-based of GW856553X on endothelial in am-matory responses, HUVEC were stimu-lated presence of 100nM GW856553X. The with TNF-α, in the absence or release after 24 hours of cytokines and chemokines MCP-1) (namely IL-8, IL-6, and modest but consistent (and statistically was measured. We observed signi cant) lease (Figs. 6a-c). However, inhibition inhibition of cytokine re-was 37% for IL-6, 41% for IL-8 in Figs. 6a-less than 50% (24% for MCP-1, c). Addition of higher concentrations of GW856553X inhibition rable modest inhibitory effect was seen (data did not not shown). A result in compa-further when (data IL-1β was used as a stimulus tions, HUVEC viability, assessed using not shown). Under these condi-MTT, was unaffected (data not shown).VEGF, vivoa key gration , was used to promote HUVEC mi-angiogenic stimulus in membrane across an 8μGW856553X did not affect the chemo-in vitro. However, m polycarbonate 100nM tactic tubule formation by AngioKit (see response (Fig. 6d). In contrast, terials CD31 and Methods), Ma-concentration-dependent expression, was as inhibited assessed by 7).
fashion (Fig. in a Discussion
The characterisation of p38 MAPK as a key player in in ammation more than 10 years ago has led to the development of the treatment of in ammatory autoim-several p38 MAPK inhibitors for mune MAPK diseases. inhibitors Several have synthetic demonstrated
p38 To determine the effect on established disease, mice were treated with either GSK678361 10mg/kg Fig. 5. p38 MAPK inhibition reverses joint destruction in chronic CIA.
daily from day 1 of arthritis, or with vehicle from day 1 followed by 10mg/kg daily GSK678361 from day 14 of arthritis (n=5-7 per group). At the end of the study (day 29), animals were sacri ced and paws were sectioned for histological evaluation. Haematoxylin and eosin sections were scored in a blinded fashion for pannus formation, synovitis, bone and cartilage erosion. Representative sections are shown as 10mg/kg GSK678361 from day 14 of arthritis. (follows: (a) untreated, (b) vehicle-treated, (c) 10mg/kg GSK678361 from day 1 of arthritis (d) animal sacri ced on day 14 of arthritis. (e) Panel shows a paw section from a vehicle-treated erate synovitis with some loss of cartilage; 2=extensive synovial hyperplasia, destruction of cartilage f) Paws were assigned one of three grades: 0=normal; 1=mod-and some bone erosions. Results are mean (± SEM) histological score (metatarsal, tibia-tarsus, proxi-mal interphalangeal and distal interphalangeal joints). Statistical analysis was carried out by 1-way ANOVA versus vehicle-treated mice: ***p<0.001.
protective anti-in ammatory effects in animal models of arthritis, such as CIA inhibitory in mice or adjuvant-induced arthritis in intracellular capacity, regardless of high Lewis rats (17-22). However, none of Two ATP concentrations (23). these BIRB-796 and RWJ-67657, have dem-different p38 MAPK inhibitors, passed early clinical trials for the treat-molecules has yet successfully onstrated ment endotoxin clinical such as RA, because of safety concerns of human autoimmune diseases inhibition of p38 MAPK was shown to challenge ef cacy model in in a human which related decrease LPS-induced cytokine and C-with reactive protein production can bind to both the active and inactive other to kinases. possible These cross-reactivities compounds to in vivo and forms of p38, providing an advantage toms, for example those of sepsis (such reduce LPS-induced clinical symp-over ATP and resulting in a very potent
as increased heart rate, decreased blood pressure, fever, and headache) (24, 25).
182
p38 inhibition and not MK2 inhibition enhances ...efficacy in in vitro and in vivo inflammatory ... Novel inhibitor of p38 MAP kinase as an anti...
(2013) In Vitro and In Vivo Experimental Models...Efficacy of Antineoplastic Drugs on Urinary Bladder...inhibition are the oldest and most commonly used ...
The potent anti-leukemia efficacy of Icaritin in murine model demonstrated ... Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a...
of 4T1 breast cancer in vitro and in vivo. ...In vivo growth-inhibition of Sarcoma 180 by ...Chemopreventive efficacy of curcumin and piperine ...
namely stimulation of osteoblastic cell proliferation and inhibition of ...In summary, the present study clearly demonstrates the in vivo efficacy of ...
Experimental models of elevated Pgc in vivo ...In vitro mechanical stimulation therefore represents ...of p38 MAP kinase and subsequent inhibition by ...
Target validation Seattle/Chicago: Structure ...(in vitro systems) Biochemical (kinase, protease,...Inhibition Slide 20 deCODE Capabilities: In Vivo ...
In vitro models (enzyme inhibition, receptor ...and in silico) Bottleneck: Target validation, “... www.kubinyi.de MAP Kinase Pathways Kinases www....
[1] Target: p38 MAPK in vitro: In SHR-SPs receiving a salt-fat diet...Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, ...
Efficacy of a Tyrosine... 暂无评价 9页 免费 ...in vitro screening for tyrosine kinase inhibitors ...Also, there is substantial in vivo inhibition of...
热门文档